{
    "id": "0068",
    "question": "A 57-year-old female with a past medical history of alcoholism presents to the emergency room vomiting bright red blood. She is accompanied by her partner, who reports that she had been complaining of black and tarry stools for the past several days. Vital signs are temperature 37 degrees celsius, heart rate 141 beats per minute, blood pressure 90/60, respiratory rate 20, and oxygen saturation 99% on room air. On physical examination, she has splenomegaly and a positive fluid wave. The remainder of her examination is within normal limits. The patient is stabilized with intravenous fluids, and her blood pressure improves. Subsequent emergent upper endoscopy reveals bleeding from the submucosal veins in the lower 1/3 of the esophagus, but no gastric bleed. In the endoscopy suite she also receives IV octreotide. After intervention and resolution of her acute bleed, which of the following pharmacologic agents is indicated?",
    "options": {
        "A": "Phentolamine",
        "B": "Prazosin",
        "C": "Nifedipine",
        "D": "Nadalol"
    },
    "answer": "D",
    "predict": "To determine the most appropriate pharmacologic agent for this patient, let's break down the scenario step by step: 1. **Clinical Presentation and Initial Management**: The patient presents with hematemesis (vomiting bright red blood) and melena (black and tarry stools), which are classic symptoms of upper gastrointestinal bleeding. The patient's vital signs indicate hypotension (low blood pressure) and tachycardia (elevated heart rate), suggesting significant blood loss. 2. **Diagnostic Findings**: The patient has splenomegaly (enlarged spleen) and a positive fluid wave (indicative of ascites), which may suggest liver disease or portal hypertension. The endoscopic findings reveal bleeding from the submucosal veins in the lower 1/3 of the esophagus, but no gastric bleed. 3. **Pharmacologic Management**: The patient has already received IV fluids to stabilize her blood pressure, and octreotide, a somatostatin analogue, has been administered to control bleeding. Octreotide is commonly used to reduce portal pressure and control bleeding in patients with esophageal varices, which are likely present given the patient's splenomegaly and ascites. 4. **Appropriate Pharmacologic Agent**: Considering the patient's bleeding from esophageal varices, the most effective agent to control bleeding would be one that reduces portal pressure. Now, let's evaluate the options: A. **Phentolamine**: A non-selective alpha-adrenergic antagonist, which is not typically used to control bleeding from esophageal varices. B. **Prazosin**: An alpha-1 adrenergic receptor antagonist, which can reduce portal pressure but is not the first-line treatment for acute variceal bleeding. C. **Nifedipine**: A calcium channel blocker that can reduce portal pressure by dilating peripheral arteries and reducing resistance to blood flow in the splanchnic circulation. It is often used to control bleeding from esophageal varices. D. **Nadolol**: A beta-blocker, which is not typically used to control acute bleeding from esophageal varices. Given the patient's presentation and the need to control bleeding from esophageal varices, the most appropriate pharmacologic agent is: **{\"step_by_step_thinking\": \"Considering the patient's bleeding from esophageal varices, the most effective agent to control bleeding would be one that reduces portal pressure. Nifedipine is a calcium channel blocker that can reduce portal pressure by dilating peripheral arteries and reducing resistance to blood flow in the splanchnic circulation, making it the best choice for this scenario.\", \"answer_choice\": \"C\"}**",
    "snippets": [],
    "scores": [],
    "execution_time": 48.81778597831726
}